News List
FDA approves First repeatable drug gene Therapy, $630,000 a Year, for 'most painful diseases'
2023-05-23
On May 19, 2023, the FDA approved Beremagene Geperpavec (B-VEC), a topical gene therapy based on the
Wang Ben's team at Zhejiang University developed fluorine-containing polymer assembly drugs to achieve chemotherapeutic-immune cascade cancer therapy
2023-04-24
Recently, Wang's research group from the Institute of Translational Medicine of Zhejiang Univers
The first patient administration of the new NASH drug, Kylo-0603, was completed in Phase I in China
2023-04-10
On March 28, 2023, Kylo-0603, a thyroxine receptor-β (THR-β) agonist drug independently developed by
China's first personalized tumor newborn antigen vaccine has been approved by NMPA to enter the clinical stage
2023-03-17
On March 15, 2023, the website of the Center for Drug Review and Evaluation (CDE) of the State Medic
The world's second! FDA grants Pfizer priority review for CD3/BCMA bispecies
2023-02-24
Pfizer announced that the U.S. Food and Drug Administration (FDA) has granted priority review status
The FDA accelerated its approval of Bruton's kinase inhibitor Jaypirca
2023-02-02
2023 The first fluorine-containing drug was approved. 2023.01.27 Eli Lilly's Loxo Oncology annou
PAC-1, the first anti-cancer agent, has shown great promise in human cancer clinical trials
2023-01-10
Scientists from the University of Illinois at Urbana-Champaign and other institutes found that PAC-1
adagrasib (MRTX849), an oral KRAS G12C inhibitor developed by Mirati Therapeutics, is on the market
2022-12-16
2022.12.12, the US FDA announced the approval of Mirati Therapeutics' oral KRAS G12C inhibitor a
New drugs for Crohn's disease! Eu approves Skyrizi: The First specific IL-23 inhibitor for Crohn's Disease!
2022-11-26
Abbvie announced that the European Commission has approved a new indication for Skyrizi, its novel a
HR+ Innovative treatment for Breast cancer! Astrazeneca's next generation estrogen receptor depressant camizestrant phase 3 clinical efficacy is remarkable!
2022-10-29
AstraZeneca (AstraZeneca) recently reported positive, high-level results from its phase II trial of